$Eton Pharmaceutical (ETON.US)$Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 3 MINUTES AGO, 6:50 AM EDT VIA GLOBENEWSWIRE - Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 -
$Eton Pharmaceutical (ETON.US)$Eton Pharmaceuticals Announced The Full Readout From The Clinical Trial Evaluating PKU GOLIKE As A Protein Substitute For Phenylketonuria In Patients During Prolonged Fasting Periods Benzinga· 5 mins ago1min The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels,...
$Eton Pharmaceutical (ETON.US)$ Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus. The product, already approved by the European Medicines Agency since 2018, has received Orphan Drug Designation from the FDA. Amglidia is a patented liquid formulation targeting approximately 300 U.S. patients with neonatal dia...
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Eton Pharmaceutical Stock Forum
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial
3 MINUTES AGO, 6:50 AM EDT
VIA GLOBENEWSWIRE
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -
- Company expects to submit New Drug Application (NDA) in April 2025 -
Only FDA-Approved Zinc Treatment for Wilson Disease Now Available - What Makes Galzin Different?
3 mins ago
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (Zinc Acetate) Capsules
Major Patent Win: Eton's Game-Changing Liquid Diabetes Drug Gets 20-Year Protection
just
Eton Pharmaceuticals Closes Acquisition of Increlex® (Mecasermin Injection)
Benzinga· 5 mins ago1min
The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels,...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals has acquired U.S. rights to Amglidia (glyburide oral suspension) from AMMTeK for treating neonatal diabetes mellitus.
The product, already approved by the European Medicines Agency since 2018, has received Orphan Drug Designation from the FDA. Amglidia is a patented liquid formulation targeting approximately 300 U.S. patients with neonatal dia...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
No comment yet